Pricing Log in Create free account
Monday 2 November 2026 Export NUS’s income statement to Excel — free account

Nu Skin Enterprises, Inc.

NUS Consumer Defensive Household & Personal Products

Nu Skin Enterprises, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 14.3% from fiscal 2024.

Revenue
−17.1%
EPS
−1,295.4%
Free cash flow
−86.1%
Total debt
−14.2%

Quarter to June 2026, against a year earlier

4.78 0.13 +2.80%
Market cap
$226.4M
P/E
0.0×
Fwd P/E
−1.0×
Dividend yield
5.02%
F-score
7/9
Altman Z
3.78
Beneish M
−2.35
Dividend safety
70/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.10
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — 1 2 — — — — —
Insider Ownership 2.79%

Capital & Financial Ratios $m

Size
Market Cap 226.35
Revenue ttm 1,375.25
Net income ttm (216.39)
Free cash flow ttm 10.78
Net debt Q 22.28
Valuation
P/E 0.00
Forward P/E (0.99) (negative: loss-making)
Price / sales 0.17
Forward P/S Powerpack
Price / FCF 21.55
Price / book 0.43
Financial health
Current ratio Q 1.98 (at or above 1.5: strong)
Debt / equity Q 0.39 (at or below 0.5: strong)
Interest coverage Q (17.86)
Growth
Revenue growth Q −17.10% (below 0%: shrinking)
Operating income growth Q −292.72% (below 0%: shrinking)
EPS, this year −35.43% (below 0%: weak)
EPS, next year A +41.46% (at or above 15%: strong)
Revenue, next year A −11.32% (below 0%: weak)
EPS, past 5 yrs −2.61% (below 0%: weak)
EPS, next 5 yrs A −6.46% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.2×, against a ten-year median of 0.9×; over the ten years it ranged from 0.2× in 2026 to 1.9× in 2018.
P/S against its own 10 years 1.58%
10-year low 10-year high
P/B against its own 10 years 3.45%
10-year low 10-year high
EV/Sales against its own 10 years 1.62%
10-year low 10-year high
EV/FCF against its own 10 years 81.53%
10-year low 10-year high

Dividends

Yield
5.02%
Annual rate
0.24
Payout ratio
—
Growth, 2016–25
−17.9%/yr
  1. 1.42 ’16
  2. 1.44 ’17 +1%
  3. 1.46 ’18 +1%
  4. 1.48 ’19 +1%
  5. 1.50 ’20 +1%
  6. 1.52 ’21 +1%
  7. 1.54 ’22 +1%
  8. 1.56 ’23 +1%
  9. 0.24 ’24 −85%
  10. 0.24 ’25 +0%
  11. 0.24 ’26e +0%
paid forecast

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 268 198 240 191
Receivables 59 51 40 49
Inventory 280 190 179 191
Other 14 27 — —
702 539 548 508
2023 2024 2025 Q'26
Payables 43 35 26 38
ST’ Debt 25 30 20 20
Other 7 14 — —
329 297 264 256

Compound Annual Growth %

10y 5y 3y
Sales (4.06%) (10.47%) (12.61%)
Cash Flow (12.97%) (26.69%) (9.43%)
Earnings 1.87% (3.49%) 15.20%
Book Value (0.25%) (2.08%) (3.54%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.20 Actual 0.20

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.30 0.34 Beat by 0.04
Q4 FY25 0.30 0.29 Miss by 0.01
Q1 FY26 0.15 0.14 Miss by 0.01
Q2 FY26 0.20 0.20 Met by 0.00
Q3 FY26 0.21 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.04 (5.14) — — —
’25 2.14 0.43 0.34 0.29 3.18
’24 (0.01) (2.38) 0.17 (0.73) (2.95)
’23 0.23 0.54 (0.74) 0.15 0.17
’22 0.76 0.67 (0.51) 1.15 2.07
’21 0.91 1.15 0.97 (0.18) 2.86
’20 0.36 0.81 1.08 1.40 3.63
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 321 320 — — —
’25 364 386 364 370 1,485
’24 417 439 430 446 1,732
’23 481 500 499 489 1,969
’22 605 561 538 522 2,226
’21 677 704 641 673 2,696
’20 518 612 703 748 2,582
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) 11 — — —
’25 0 36 27 17 80
’24 3 51 31 26 112
’23 (22) 36 51 54 119
’22 8 47 28 26 108
’21 (19) 21 30 110 142
’20 69 97 118 95 379
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (18) 5 — — —
’25 (13) 36 18 6 46
’24 (9) 43 23 13 70
’23 (34) 21 39 34 60
’22 (3) 37 3 12 49
’21 (38) 3 17 91 73
’20 50 88 98 80 315
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 2,208 2,279 2,679 2,420 2,582 2,696 2,226 1,969 1,732 1,485 1,375 (4.3%) 1,317 1,474 — (0.4%)
Gross margin, % 77.33 77.97 76.33 75.98 74.51 74.95 71.65 68.93 68.23 69.45 69.19 (7.9) pt
EBT 213 266 220 255 256 232 89 27 (175) 196 (26) (0.9%)
EBT margin, % 9.64 11.65 8.20 10.54 9.92 8.62 4.00 1.35 (10.11) 13.21 (1.92) +3.6 pt
Net income 143 129 122 174 191 147 105 9 (147) 160 (216) +1.3%
Per share, $
Per share, $ Revenue 39.84 43.16 48.56 43.60 49.37 53.71 44.51 39.61 34.88 30.13 28.30 (3.1%)
Earnings 2.58 2.45 2.21 3.13 3.66 2.93 2.10 0.17 (2.95) 3.25 (4.45) +2.6%
Cash flow 4.97 5.73 3.67 3.20 7.25 2.82 2.16 2.39 2.25 1.63 1.05 (11.7%)
Capex (0.91) (1.14) (1.28) (1.19) (1.22) (1.37) (1.18) (1.18) (0.84) (0.70) (0.82) (2.9%)
Free cash flow 4.06 4.59 2.40 2.01 6.03 1.45 0.98 1.21 1.41 0.93 0.22 (15.1%)
Book value 11.98 13.34 14.17 15.77 17.10 18.19 17.95 16.53 13.12 16.34 11.17 +3.5%
Shares, m 55 53 55 56 52 50 50 50 50 49 49 (1.3%)
Valuation, ×
Valuation, × P/E 18.83 27.98 27.63 13.13 14.73 17.38 20.12 112.89 0.00 2.97 0.00 25.6
P/S 1.22 1.59 1.26 0.94 1.11 0.95 0.95 0.51 0.20 0.32 0.17 0.9
P/B 4.07 5.14 4.33 2.60 3.19 2.79 2.35 1.23 0.53 0.59 0.43 2.7
EV/Sales 1.25 1.57 1.28 0.95 1.07 0.95 1.00 0.63 0.31 0.31 0.19 0.9
EV/FCF 12.23 14.73 25.81 20.50 8.78 35.20 45.64 20.70 7.67 9.97 23.61 20.1
Cash, $m
Cash, $m Operating cash flow 275 303 203 178 379 142 108 119 112 80 51 (12.8%)
Capex (50) (60) (70) (66) (64) (69) (59) (58) (42) (34) (40) (4.2%)
Free cash flow 225 242 132 112 315 73 49 60 70 46 11 (16.2%)
Balance, $m
Balance, $m Working capital 315 330 360 383 360 343 401 373 242 284 252 (1.2%)
Net debt 49 (50) 32 18 (89) 21 124 235 196 (16) 22 n/m
Shareholders’ equity 664 705 782 875 894 913 897 822 651 805 543 +2.2%
Returns, %
Returns, % ROA 9.60 8.45 7.42 10.02 10.27 7.62 5.62 0.47 (8.95) 11.15 (16.87) +1.6 pt
ROIC 20.26 26.19 18.49 18.71 19.98 15.65 6.78 2.85 (11.18) 5.21 (1.15) (15.0) pt
ROE 19.21 18.91 16.40 20.95 21.63 16.30 11.58 1.00 (19.90) 22.00 (32.53) +2.8 pt
People
People Employees 4,650 4,700 4,900 4,900 5,000 4,600 3,800 3,700 3,100 2,800 — (5.5%)
Revenue/emp, $m 0.47 0.48 0.55 0.49 0.52 0.59 0.59 0.53 0.56 0.53 — +1.2%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Nu Skin Enterprises, Inc. vs peers in Household & Personal Products (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ODD ODDITY Tech Ltd. $999.5M 69.4× — (loss-making) −25.14% (below 0%: shrinking) −68.97% (below 0%: shrinking) −7.74% (below 0%: shrinking) 68.66% (0.70%) Compare
HELE Helen of Troy Limited $675.8M — (loss-making) 8.1× +2.12% (above 0%: growing) n/m +304.51% (above 0%: growing) 52.19% 5.20% Compare
HNST The Honest Company, Inc. $447.4M — (loss-making) 44.9× −10.87% (below 0%: shrinking) +233.33% (above 0%: growing) +3,911.74% (above 0%: growing) 48.45% 11.50% Compare
MAGN Magnera Corporation $422.4M — (loss-making) — (loss-making) +2.15% (above 0%: growing) n/m −115.38% (below 0%: shrinking) 13.07% 2.57% Compare
ACU Acme United Corporation. $257.9M 26.9× 25.5× +16.15% (above 0%: growing) +4.76% (above 0%: growing) +155.61% (above 0%: growing) 42.55% 10.89% Compare
NUS Nu Skin Enterprises, Inc. $226.4M — (loss-making) — (loss-making) −17.10% (below 0%: shrinking) n/m −86.06% (below 0%: shrinking) 68.20% (18.53%)
YSG Yatsen Holding Limited Sponsored ADR $143.5M — (loss-making) — (loss-making) +10.97% (above 0%: growing) n/m +14.56% (above 0%: growing) 73.88% (11.55%) Compare
SKIN SkinHealth Systems Inc. $64.7M — (loss-making) — (loss-making) −7.77% (below 0%: shrinking) n/m −81.89% (below 0%: shrinking) 68.42% 4.95% Compare
SLSN Solesence, Inc. $60.1M — (loss-making) — −24.69% (below 0%: shrinking) n/m +86.52% (above 0%: growing) 30.97% 0.79% Compare
Median of peers $340.2M — 25.5× −2.83% +4.76% +50.54% 50.32% 3.76%

All 31 Household & Personal Products stocks →

Nu Skin Enterprises, Inc. (NUS) Latest News

22 Oct

Impact 3 · · Business Wire

11 Aug

Impact 3 · · MarketBeat transcript

10 Aug

Impact 3 ·
Impact 3 · · Moby transcript

18 May

Impact 3 · · Simply Wall St.

13 May

Impact 4 · · MarketBeat

8 May

Impact 4 · · Moby

7 May

Impact 4 · · Business Wire
Impact 3 · · Zacks

2 Apr

Impact 4 · · Business Wire

13 Feb

Impact 4 · · Moby transcript
Impact 4 · · MarketBeat transcript
Impact 4 ·
Impact 3 · · Zacks
Impact 3 · · TMX Newsfile

12 Feb

Impact 3 · · ZacksMT NewswiresZacksZacksZacksZacks
Impact 3 · · Associated Press Finance
Impact 3 · · Business Wire

11 Feb

Impact 3 · · Zacks24/7 Wall St.Motley FoolBarchartMotley Fool24/7 Wall St.Motley FoolGOBankingRates

6 Feb

Impact 3 · · Business Wire

14 Jan

Impact 3 · · TMX Newsfile
Impact 3 · · Business Wire

9 Jan

Impact 3 · · Business Wire

4 Jan

Impact 3 · · Simply Wall St.

30 Dec

Impact 3 · · Business Wire
Impact 3 · · Zacks

23 Dec

Impact 3 · · ZacksZacks

18 Dec

Impact 4 · · Business WireZacksSimply Wall St.WWDMT NewswiresWWDZacks
Impact 4 · · ZacksStockStory

17 Dec

Impact 3 · · ZacksZacksZacks
stockrow.com/NUS · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com